-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, S/NiTrslw1NORkbvcB7l1GHsK+7IvpoKtU+E9j9AkCsbvqC1HFr89gB017C8R3Wf B7eOJHC+DMz1+89yn22XTg== 0001144204-04-007471.txt : 20040524 0001144204-04-007471.hdr.sgml : 20040524 20040524111143 ACCESSION NUMBER: 0001144204-04-007471 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20040521 ITEM INFORMATION: Other events ITEM INFORMATION: Financial statements and exhibits FILED AS OF DATE: 20040524 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HALOZYME THERAPEUTICS INC CENTRAL INDEX KEY: 0001159036 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 880488686 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-49616 FILM NUMBER: 04825805 BUSINESS ADDRESS: STREET 1: 11588 SORRENTO VALLEY ROAD STREET 2: SUITE 17 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: (858) 794-8889 FORMER COMPANY: FORMER CONFORMED NAME: GLOBAL YACHT SERVICES INC DATE OF NAME CHANGE: 20010912 8-K 1 v03638.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _________________________ FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) May 21, 2004 HALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 000-49616 88-0488686 --------------------------- ---------------------- ------------ (State or other jurisdiction (Commission File Number) (IRS Employer of incorporation) Identification No.) 11588 Sorrento Valley Road, Suite 17 San Diego, California 92121 (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code (858) 794-8889 -------------- Not Applicable (Former name or former address, if changed since last report) ITEM 5. OTHER EVENTS AND REGULATION FD DISCLOSURE. On May 24, 2004, Halozyme Therapeutics, Inc. ("Halozyme") issued a press release that Kenneth Kelley had been named to its Board of Directors. In addition, Edward Mercaldo resigned from the Board of Directors. The foregoing is discussed in greater detail in such press release, a copy of which is filed herewith as Exhibit 99.1. ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS (c) Exhibits. The following Exhibit is filed with this Form 8-K. Exhibit No. Description ----------- ------------ 99.1 Press Release of May 24, 2004, regarding the appointment of Kenneth Kelley to the Board of Directors and the resignation of Edward Mercaldo from the Board of Directors. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. HALOZYME THERAPEUTICS, INC. Date: May 24, 2004 By: /s/ Jonathan E. Lim ------------------------------------- President and Chief Executive Officer EX-99.1 2 v03638_ex99.txt [HALOZYME THERAPEUTICS LOGO] HALOZYME CONTACT INVESTOR RELATIONS CONTACTS David A. Ramsay Ina McGuinness or Bruce Voss Chief Financial Officer Lippert/Heilshorn & Associates (858) 794-8889 (310) 691-7100 dramsay@halozyme.com imcguinness@lhai.com MEDIA CONTACTS Kathy Sweeney/ Megan Riggs Mentus 858-455-5500, x212/x215 kwitz@mentus.com megan@mentus.com HALOZYME THERAPEUTICS NAMES KENNETH KELLEY TO BOARD OF DIRECTORS EDWARD MERCALDO STEPS DOWN TO FOCUS ON OTHER BUSINESS INTERESTS SAN DIEGO, CALIF., MAY 24, 2004 - Halozyme Therapeutics, Inc. (OTCBB: HZYM), a therapeutically driven biopharmaceutical company focused on the development and commercialization of recombinant human enzymes, today announced that Kenneth Kelley has been named to its Board of Directors. In addition, Edward Mercaldo is stepping down from the board to pursue other business activities. "We are extremely pleased that Ken has agreed to join our board," said Dr. Lim. "Ken brings extensive strategic and operational biotechnology experience to Halozyme and can assist the company in its progress towards commercialization of its first products. At the same time, we are sorry to see Ed step down, as he has made an invaluable contribution to Halozyme's early development. We wish Ed the best as he focuses on his other business interests." Mr. Kelley brings over 20 years of entrepreneurial, venture capital, operational, and technical biotechnology experience to Halozyme. He is an active investor and mentor to biotechnology entrepreneurs and serves on three private company boards. Previously, he was a General Partner at Latterell Venture Partners, where he made investments in early stage biotechnology and medical device startups. Ken founded and led IntraBiotics Pharmaceuticals (NASDAQ: IBPI), serving as Founder, CEO, Director and Chairman. Over 8 years from startup, Ken led a team that discovered and developed a new class of antibiotics from lead through phase III clinical trials, raised over $100 million of venture capital and international corporate partnerships, and took the company public in 2000. Earlier, Ken was an Associate at Institutional Venture Partners (IVP), where he participated in the financing of 20 biotech and medical companies resulting in 15 IPO's. Prior to IVP, Ken was a consultant for McKinsey & Company and a scientist at Integrated Genetics (acquired by Genzyme). He has an MBA from Stanford and a BA in biochemical sciences from Harvard. Halozyme's recombinant human enzyme technology replaces current animal slaughterhouse-derived enzymes that carry risks of animal pathogen contamination and immunogenicity. The Company believes that the versatility of its first enzyme, rHuPH20, will enable Halozyme to simultaneously market the product as a medical device, a drug enhancement agent, and a therapeutic biologic. ABOUT HALOZYME THERAPEUTICS, INC. Halozyme is a therapeutically driven biopharmaceutical company dedicated to the development and commercialization of recombinant human enzymes for the infertility, ophthalmology, and oncology communities. The company's broad product portfolio is based on intellectual property covering the family of human enzymes known as hyaluronidases. The company's lead products offer a safe and pure alternative to existing slaughterhouse-derived extracts that carry risks of animal pathogen contamination and immunogenicity. The commercialization of Halozyme's highly versatile enzyme technology within proven markets will enable the company to significantly impact the quality of medicine. SAFE HARBOR STATEMENT In addition to historical information, the statements set forth above include forward-looking statements (including, without limitation, statements concerning the marketing and distribution methods Halozyme intends to employ with respect to its first enzyme) that involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are also identified through use of the words "believes," "execute," "enable" and other words of similar meaning. Factors that may result in differences are discussed in greater detail in Halozyme Therapeutics' Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. # # # -----END PRIVACY-ENHANCED MESSAGE-----